Anti‐CD38 therapeutic antibodies have been fundamental in advancing the treatment of multiple myeloma [17, 18], while gaining relevance through an increasing number of off‐label uses and clinical trials for the treatment of further plasma cell disorders and hematologic malignancies [19–22] as well as treatment of kidney disorders [23–27], autoimmune disorders [27, 28], antibody‐mediated rejection after organ transplantation [29–31] and desensitization prior to transplantation [32, 33]. This evidence concerns the gene CD38 and kidney disorder.